Targeted radiation drug takes aim at bone metastases in advanced cancer
NCT ID NCT07087197
First seen Sep 30, 2025 · Last updated Jun 20, 2026 · Updated 29 times
Summary
This early-stage trial is testing a new drug called SKB107, which delivers radiation directly to bone tumors. It is for people with advanced solid tumors (like breast, prostate, or lung cancer) that have spread to the bones and who have run out of standard treatment options. The study will enroll about 90 participants to check the drug's safety, how it moves through the body, and whether it can slow bone tumor growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SKB107 (a radioactive drug that targets bone)
What this could lead to
If it works, this could provide a new treatment option for people with advanced cancer that has spread to the bones, potentially slowing bone tumor growth.
What could go wrong
This is an early Phase 1 trial with only 90 participants, so safety and effectiveness are not yet proven. The radioactive drug may cause side effects like bone marrow suppression or damage to healthy organs.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.